Semaphorin 3F Expression is Reduced in Pregnancy Complicated by Preeclampsia. An Observational Clinical Study

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Mar 29

PMID 28350837

Citations 6

Authors

Giovanni Stallone

Maria Matteo

Giuseppe Stefano Netti

Barbara Infante

Adelaide Di Lorenzo

Clelia Prattichizzo

Stefania Carlucci

Federica Trezza

Loreto Gesualdo

Pantaleo Greco

Giuseppe Grandaliano

Affiliations

Soon will be listed here.

Abstract

Background And Objective: Preeclampsia is a systemic disorder, affecting 2-10% of pregnancies, characterized by a deregulated pro- and anti-angiogenic balance. Semaphorin 3F is an angiogenesis inhibitor. We aimed to investigate whether semaphorin 3F expression is modulated in preeclampsia.

Design, Setting, Participants, And Measurements: We performed two observational single center cohort studies between March 2013 and August 2014. In the first we enrolled 110 consecutive women, undergoing an elective cesarean section; in the second we included 150 consecutive women undergoing amniocentesis for routine clinical indications at 16-18 week of gestation. Semaphorin 3F concentration was evaluated in maternal peripheral blood, venous umbilical blood and amniotic fluid, along with its placenta protein expression at the time of delivery in the first study group and in the amniotic fluid at 16-18 weeks of gestation in the second study group.

Results: In the first study 19 patients presented at delivery with preeclampsia. Semaphorin 3F placenta tissue expression was significantly reduced in preeclampsia. In addition, semaphorin 3F level at delivery was significantly lower in serum, amniotic fluid and venous umbilical blood of preeclamptic patients compared with normal pregnant women. In the prospective cohort study 14 women developed preeclampsia. In this setting, semaphorin 3F amniotic level at 16-18 weeks of gestation was reduced in women who subsequently developed preeclampsia compared to women with a normal pregnancy. ROC curve analysis showed that semaphorin 3F amniotic levels could identify women at higher risk of preeclampsia.

Conclusions: Semaphorin 3F might represent a predictive biomarker of preeclampsia.

Citing Articles

Semaphorin 3A Increases in the Plasma of Women with Diminished Ovarian Reserve Who Respond Better to Controlled Ovarian Stimulation.

Palese M, Ferretti G, Perruolo G, Serafini S, Sirabella R, Marrone V Life (Basel). 2024; 14(3).

PMID: 38541683 PMC: 10971200. DOI: 10.3390/life14030358.

Characterization of Cytotoxic T Lymphocytes (CTL) by Tissue Microarray.

Netti G, Rutigliano M, Divella C, Lucarelli G Methods Mol Biol. 2021; 2325:107-124.

PMID: 34053054 DOI: 10.1007/978-1-0716-1507-2_8.

PTX3 modulates the immunoflogosis in tumor microenvironment and is a prognostic factor for patients with clear cell renal cell carcinoma.

Netti G, Lucarelli G, Spadaccino F, Castellano G, Gigante M, Divella C Aging (Albany NY). 2020; 12(8):7585-7602.

PMID: 32345771 PMC: 7202504. DOI: 10.18632/aging.103169.

Serum Levels of BAFF and APRIL Predict Clinical Response in Anti-PLA2R-Positive Primary Membranous Nephropathy.

Netti G, Infante B, Spadaccino F, Godeas G, Corallo M, Prisciandaro C J Immunol Res. 2019; 2019:8483650.

PMID: 31781684 PMC: 6874868. DOI: 10.1155/2019/8483650.

Deletion of Semaphorin 3F in Interneurons Is Associated with Decreased GABAergic Neurons, Autism-like Behavior, and Increased Oxidative Stress Cascades.

Li Z, Jagadapillai R, Gozal E, Barnes G Mol Neurobiol. 2019; 56(8):5520-5538.

PMID: 30635860 PMC: 6614133. DOI: 10.1007/s12035-018-1450-9.

References

Bielenberg D, Hida Y, Shimizu A, Kaipainen A, Kreuter M, Kim C . Semaphorin 3F, a chemorepulsant for endothelial cells, induces a poorly vascularized, encapsulated, nonmetastatic tumor phenotype. J Clin Invest. 2004; 114(9):1260-71. PMC: 524226. DOI: 10.1172/JCI21378. View

Burton G, Jauniaux E . Placental oxidative stress: from miscarriage to preeclampsia. J Soc Gynecol Investig. 2004; 11(6):342-52. DOI: 10.1016/j.jsgi.2004.03.003. View

Roche J, Boldog F, Robinson M, Robinson L, Varella-Garcia M, SWANTON M . Distinct 3p21.3 deletions in lung cancer and identification of a new human semaphorin. Oncogene. 1996; 12(6):1289-97. View

Wyatt S, Kraus F, Roh C, Elchalal U, Nelson D, Sadovsky Y . The correlation between sampling site and gene expression in the term human placenta. Placenta. 2005; 26(5):372-9. DOI: 10.1016/j.placenta.2004.07.003. View

Coma S, Shimizu A, Klagsbrun M . Hypoxia induces tumor and endothelial cell migration in a semaphorin 3F- and VEGF-dependent manner via transcriptional repression of their common receptor neuropilin 2. Cell Adh Migr. 2011; 5(3):266-75. PMC: 3210211. DOI: 10.4161/cam.5.3.16294. View

Redman C, Sargent I . Placental stress and pre-eclampsia: a revised view. Placenta. 2009; 30 Suppl A:S38-42. DOI: 10.1016/j.placenta.2008.11.021. View

Maynard S, Min J, Merchan J, Lim K, Li J, Mondal S . Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003; 111(5):649-58. PMC: 151901. DOI: 10.1172/JCI17189. View

Wang G, Semenza G . Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995; 270(3):1230-7. DOI: 10.1074/jbc.270.3.1230. View

Chaiworapongsa T, Romero R, Korzeniewski S, Kusanovic J, Soto E, Lam J . Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol. 2013; 208(4):287.e1-287.e15. PMC: 4086897. DOI: 10.1016/j.ajog.2013.01.016. View

10.

Chen H, Chedotal A, He Z, Goodman C, Tessier-Lavigne M . Neuropilin-2, a novel member of the neuropilin family, is a high affinity receptor for the semaphorins Sema E and Sema IV but not Sema III. Neuron. 1997; 19(3):547-59. DOI: 10.1016/s0896-6273(00)80371-2. View

11.

Hirota K, Semenza G . Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol. 2006; 59(1):15-26. DOI: 10.1016/j.critrevonc.2005.12.003. View

12.

Romero R, Nien J, Espinoza J, Todem D, Fu W, Chung H . A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a.... J Matern Fetal Neonatal Med. 2008; 21(1):9-23. PMC: 2587364. DOI: 10.1080/14767050701830480. View

13.

Redman C, Sargent I . Latest advances in understanding preeclampsia. Science. 2005; 308(5728):1592-4. DOI: 10.1126/science.1111726. View

14.

Resta L, Capobianco C, Marzullo A, Piscitelli D, Sanguedolce F, Schena F . Confocal laser scanning microscope study of terminal villi vessels in normal term and pre-eclamptic placentas. Placenta. 2005; 27(6-7):735-9. DOI: 10.1016/j.placenta.2005.07.006. View

15.

Yazdani U, Terman J . The semaphorins. Genome Biol. 2006; 7(3):211. PMC: 1557745. DOI: 10.1186/gb-2006-7-3-211. View

16.

Stallone G, Cormio L, Netti G, Infante B, Selvaggio O, Di Fino G . Pentraxin 3: a novel biomarker for predicting progression from prostatic inflammation to prostate cancer. Cancer Res. 2014; 74(16):4230-8. DOI: 10.1158/0008-5472.CAN-14-0369. View

17.

Maulik D, De A, Ragolia L, Evans J, Grigoryev D, Lankachandra K . Down-regulation of placental neuropilin-1 in fetal growth restriction. Am J Obstet Gynecol. 2015; 214(2):279.e1-279.e9. DOI: 10.1016/j.ajog.2015.09.068. View

18.

Escudero C, Celis C, Saez T, San Martin S, Valenzuela F, Aguayo C . Increased placental angiogenesis in late and early onset pre-eclampsia is associated with differential activation of vascular endothelial growth factor receptor 2. Placenta. 2014; 35(3):207-15. DOI: 10.1016/j.placenta.2014.01.007. View

19.

Schneuer F, Roberts C, Ashton A, Guilbert C, Tasevski V, Morris J . Angiopoietin 1 and 2 serum concentrations in first trimester of pregnancy as biomarkers of adverse pregnancy outcomes. Am J Obstet Gynecol. 2013; 210(4):345.e1-345.e9. DOI: 10.1016/j.ajog.2013.11.012. View

20.

Holtan S, Creedon D, Haluska P, Markovic S . Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents. Mayo Clin Proc. 2009; 84(11):985-1000. PMC: 2770910. DOI: 10.1016/S0025-6196(11)60669-1. View